Disease-modifying therapies for tauopathies: agents in the pipeline

References

• Spillantini MG, Goedert M, Crowther RA, et al. Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci U S A. 1997;94:4113–4118.
   PubMed Web of Science ®Google Scholar
• Josephs KA, Hodges JR, Snowden JS, et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 2011;122:137–153.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609–622.
   PubMed Web of Science ®Google Scholar
• Arendt T, Stieler JT, Holzer M. Tau and tauopathies. Brain Res Bull. 2016;126:238–292.
   PubMed Web of Science ®Google Scholar
• Josephs KA. Current understanding of neurodegenerative diseases associated with the protein tau. Mayo Clin Proc. 2017;92:1291–1303.
   PubMed Web of Science ®Google Scholar
• Dickson DW, Kouri N, Murray ME, et al. Neuropathology of frontotemporal lobar degenerationtau (FTLD-Tau). J Mol Neurosci. 2011;45:384–389.
   PubMed Web of Science ®Google Scholar
• Colosimo C, Bak TH, Bologna M, et al. Fifty years of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2014;85:938–944.
   PubMed Web of Science ®Google Scholar
• Kovacs GG. Invited review: neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol. 2015;41:3–23.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Tolnay M, Love S, et al. Microtubule-associated protein tau, heparan sulphate and alpha-synuclein in several neurodegenerative diseases with dementia. Acta Neuropathol. 1999;97:585–594.
   PubMed Web of Science ®Google Scholar
• Mez J, Daneshvar DH, Kiernan PT, et al. Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football. JAMA. 2017;318:360–370.
   PubMed Web of Science ®Google Scholar
• Bussiere T, Hof PR, Mailliot C, et al. Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration. Acta Neuropathol. 1999;97:221–230.
   PubMed Web of Science ®Google Scholar
• Coughlin D, Irwin DJ. Emerging diagnostic and therapeutic strategies for tauopathies. Curr Neurol Neurosci Rep. 2017;17:72.
   PubMed Web of Science ®Google Scholar
• Irwin DJ. Tauopathies as clinicopathological entities. Parkinsonism Relat Disord. 2016;22(Suppl 1):S29–S33.
   PubMed Web of Science ®Google Scholar
• Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5‘-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702–705.
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119:1–4.
   PubMed Web of Science ®Google Scholar
• Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–2477.
   PubMed Web of Science ®Google Scholar
• Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–1014.
   PubMed Web of Science ®Google Scholar
• Höglinger GU, Respondek G, Stamelou M, et al. Movement disorder society-endorsed PSP study group. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853–864.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013; 80:496–503.
   Google Scholar
• Bang J. Spina S and Miller BL. Frontotemporal dementia. Lancet. 2015;386:1672–1682.
   PubMed Web of Science ®Google Scholar
• Coyle-Gilchrist IT, Dick KM, Patterson K, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology. 2016;86:1736–1743.
   PubMed Web of Science ®Google Scholar
• Capozzo R, Sassi C, Hammer MB, et al. Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy. Alzheimers Dement. 2017;13:858–869.
   Google Scholar
• Braak H, Braak E. Argyrophilic grains: characteristic pathology of cerebral cortex in cases of adult onset dementia without Alzheimer changes. Neurosci Lett. 1987;76:124–127.
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Cortical and subcortical argyrophilic grains characterize a disease associated with adult onset dementia. Neuropathol Appl Neurobiol. 1989;15:13–26.
   PubMed Web of Science ®Google Scholar
• Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128:755–766.
   PubMed Web of Science ®Google Scholar
• Kovacs GG, Ferrer I, Grinberg LT, et al. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 2016;131:87–102.
   PubMed Web of Science ®Google Scholar
• Rodriguez RD, Suemoto CK, Molina M, et al. Argyrophilic grain disease: demographics, clinical, and neuropathological features from a large autopsy study. J Neuropathol Exp Neurol. 2016;75:628–635.
   PubMed Web of Science ®Google Scholar
• Thal DR, Arnim von CAF, Griffin WST, et al. Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimer-related co-pathologies. J Neural Transm. 2015;122:1007–1018.
   PubMed Web of Science ®Google Scholar
• Duyckaerts C, Braak H, Brion J-P, et al. PART is part of Alzheimer disease. Acta Neuropathol. 2015;129:749–756.
   PubMed Web of Science ®Google Scholar
• Jefferson-George KS, Wolk DA, Lee EB, et al. Cognitive decline associated with pathological burden in primary age-related tauopathy. Alzheimers Dement. 2017;13:1048–1053.
   PubMed Web of Science ®Google Scholar
• Josephs KA, Murray ME, Tosakulwong N, et al. Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathol. 2017;133:705–715.
   PubMed Web of Science ®Google Scholar
• Jack CR, Knopman DS, Chételat G3 G, et al. Suspected non-Alzheimer disease pathophysiology – concept and controversy. Nat Rev Neurol. 2016;12:117–124.
   PubMed Web of Science ®Google Scholar
• Kovacs GG, Robinson JL, Xie SX, et al. Evaluating the patterns of aging-related tau astrogliopathy unravels novel insights into brain aging and neurodegenerative diseases. J Neuropathol Exp Neurol. 2017;76:270–288.
   PubMed Web of Science ®Google Scholar
• Ling H, Kovacs GG, Vonsattel JPG, et al. Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain. 2016;139:3237–3252.
   PubMed Web of Science ®Google Scholar
• Tsai RM, Boxer AL. Therapy and clinical trials in frontotemporal dementia: past, present, and future. J Neurochem. 2016;138(Suppl 1):211–221.
   PubMed Web of Science ®Google Scholar
• Young JJ, Lavakumar M, Tampi D, et al. Frontotemporal dementia: latest evidence and clinical implications. Ther Adv Psychopharmacol. 2018;8:33–48.
   PubMed Web of Science ®Google Scholar
• Boxer AL, Gold M, Huey E, et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement. 2013;9:189–198.
   PubMed Web of Science ®Google Scholar
• Weingarten MD, Lockwood AH, Hwo SY, et al. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A. 1975;72:1858–1862.
   PubMed Web of Science ®Google Scholar
• Neve RL, Harris P, Kosik KS, et al. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res. 1986;387:271–280.
   PubMed Web of Science ®Google Scholar
• Goedert M, Wischik CM, Crowther RA, et al. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A. 1988;85:4051–4055.
   PubMed Web of Science ®Google Scholar
• Drechsel DN, Hyman AA, Cobb MH, et al. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell. 1992;3:1141–1154.
   PubMed Web of Science ®Google Scholar
• Kempf M, Clement A, Faissner A, et al. Tau binds to the distal axon early in development of polarity in a microtubule- and microfilament-dependent manner. J Neurosci. 1996;16:5583–5592.
   PubMed Web of Science ®Google Scholar
• Papasozomenos SC, Binder LI. Phosphorylation determines two distinct species of tau in the central nervous system. Cell Motil Cytoskeleton. 1987;8:210–226.
   PubMed Web of Science ®Google Scholar
• LoPresti P, Szuchet S, Papasozomenos SC, et al. Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc Natl Acad Sci U S A. 1995;92:10369–10373.
   PubMed Web of Science ®Google Scholar
• Woody RW, Clark DC, Roberts GC, et al. Molecular flexibility in microtubule proteins: proton nuclear magnetic resonance characterization. Biochemistry. 1983;22:2186–2192.
   PubMed Web of Science ®Google Scholar
• Uversky VN. What does it mean to be natively unfolded? Eur J Biochem. 2002;269:2–12.
   PubMedGoogle Scholar
• Jeganathan S, von Bergen M, Mandelkow EM, et al. The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments. Biochemistry. 2008;47:10526–10539.
   PubMed Web of Science ®Google Scholar
• Lindwall G, Cole RD. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem. 1984;259:5301–5305.
   PubMed Web of Science ®Google Scholar
• Holmes BB, Diamond MI. Prion-like properties of tau protein: the importance of extracellular tau as a therapeutic target. J Biol Chem. 2014;18:19855–19861.
   Web of Science ®Google Scholar
• Goedert M, Spillantini MG, Jakes R, et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron. 1989;3:519–526.
   PubMed Web of Science ®Google Scholar
• Andreadis A, Brown WM, Kosik KS. Structure and novel exons of the human tau gene. Biochemistry. 1992;31:10626–10633.
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130–133.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205–1208.
   PubMed Web of Science ®Google Scholar
• Bigio EH, Lipton AM, Yen SH, et al. Frontal lobe dementia with novel tauopathy: sporadic multiple system tauopathy with dementia. J Neuropathol Exp Neurol. 2001;60:328–341.
   PubMed Web of Science ®Google Scholar
• Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta. 2005;1739:240–250.
   PubMed Web of Science ®Google Scholar
• Ahmed Z, Doherty KM, Silveira-Moriyama L, et al. Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Acta Neuropathol. 2011;122:415-428.
   Google Scholar
• Irwin DJ, Cairns NJ, Grossman M, et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropahol. 2015;129:469-491.
   Google Scholar
• Togo T, Sahara N, Yen SH, et al. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol. 2002;61:547–556.
   Google Scholar
• Buée L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick’s disease. Brain Pathol. 1999;9:681–693.
   PubMed Web of Science ®Google Scholar
• Kovacs GG. Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine. Int J Mol Sci. 2016;17:E189.
   PubMed Web of Science ®Google Scholar
• Feany MB, Mattiace LA, Dickson DW. Neuropathologic overlap of progressive supranuclear palsy, Pick’s disease and corticobasal degeneration. J Neuropathol Exp Neurol. 1996;55:53–67.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Weidenheim KM, Dickson DW, et al. Morphological and biochemical correlations of abnormal tau filaments in progressive supranuclear palsy. J Neuropathol Exp Neurol. 2002;61:33–45.
   PubMed Web of Science ®Google Scholar
• Zhukareva V, Mann D, Pickering-Brown S, et al. Sporadic Pick’s disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. Ann Neurol. 2002;51:730–739.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 1998;21:428–433.
   PubMed Web of Science ®Google Scholar
• Miki Y, Mori F, Hori E, et al. Hippocampal sclerosis with four-repeat tau-positive round inclusions in the dentate gyrus: a new type of four-repeat tauopathy. Acta Neuropathol. 2009;117:713–718.
   PubMed Web of Science ®Google Scholar
• Buée Scherrer V, Hof PR, Buée L, et al. Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick’s disease. Acta Neuropathol. 1996;91:351–359.
   PubMed Web of Science ®Google Scholar
• Hogg M, Grujic ZM, Baker M, et al. The L266V tau mutation is associated with frontotemporal dementia and Pick-like 3R and 4R tauopathy. Acta Neuropathol. 2003;106:323–336.
   PubMed Web of Science ®Google Scholar
• Vermersch P, Sergeant N, Ruchoux MM, et al. Specific tau variants in the brains of patients with myotonic dystrophy. Neurology. 1996;47:711–717.
   PubMed Web of Science ®Google Scholar
• Mendez MF, Shapira JS, McMurtray A, et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatr. 2007;15:84–87.
   PubMed Web of Science ®Google Scholar
• Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25:178–185.
   PubMed Web of Science ®Google Scholar
• Kishi T, Matsunaga S, Iwata N. Memantine for the treatment of frontotemporal dementia: a meta-analysis. Neuropsychiatr Dis Treat. 2015;11:2883–2885.
   PubMed Web of Science ®Google Scholar
• Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57:467–473.
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Barbanti P, Bonifati V, et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand. 2001;103:123–125.
   PubMed Web of Science ®Google Scholar
• Liepelt I, Gaenslen A, Godau J, et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement. 2010;6:70–74.
   PubMed Web of Science ®Google Scholar
• Ihl R, Frölich L, Winblad B, et al. WFSBP task force on treatment guidelines for Alzheimer‘s disease and other dementias. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer‘s disease and other dementias. World J Biol Psychiatry. 2011;12:2–32.
   PubMed Web of Science ®Google Scholar
• Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66:17–22.
   PubMed Web of Science ®Google Scholar
• Li Y, Hai S, Zhou Y, et al. Cholinesterase inhibitors for rarer dementias associated with nerological conditions. Cochrane Database Syst Rev. 2015;3:CD009444.
   Google Scholar
• Buoli M, Serati M, Caldiroli A, et al. Pharmacological management of psychiatric symptoms in frontotemporal dementia: a systematic review. J Geriatr Psychiatry Neurol. 2017;30:162–169.
   PubMed Web of Science ®Google Scholar
• O’Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017;31:147–166.
   PubMed Web of Science ®Google Scholar
• D‘Alton S, Lewis J. Therapeutic and diagnostic challenges for frontotemporal dementia. Front Aging Neurosci. 2014;6:204.
   PubMed Web of Science ®Google Scholar
• Lebouvier T1, Pasquier F, Buée L. Update on tauopathies. Curr Opin Neurol. 2017;30:589–598.
   PubMed Web of Science ®Google Scholar
• De Conti L, Borroni B, Baralle M. New routes in frontotemporal dementia drug discovery. Expert Opin Drug Discov. 2017;12:659–671.
   PubMed Web of Science ®Google Scholar
• Yokoyama JS, Karch CM, Fan CC, et al. Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathol. 2017;133:825–837.
   PubMed Web of Science ®Google Scholar
• Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015;18:794–799.
   PubMed Web of Science ®Google Scholar
• Panza F, Lozupone M, Logroscino G, et al. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019;15:73-88.
   Google Scholar
• Panza F, Solfrizzi V, Seripa D, et al. Tau-Centric targets and drugs in clinical development for the treatment of Alzheimer‘s disease. Biomed Res Int. 2016;2016:3245935.
   PubMed Web of Science ®Google Scholar
• Papazacharias A, Lozupone M, Barulli MR, et al. Bipolar disorder and frontotemporal dementia: an intriguing association. J Alzheimers Dis. 2017;55:973–979.
   PubMed Web of Science ®Google Scholar
• Hong M, Chen DC, Klein PS, et al. Lithium reduces tau phosphorylationby inhibition of glycogen synthase kinase-3. J Biol Chem. 1997;272:25326–25332.
   PubMed Web of Science ®Google Scholar
• Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA. 2005;102:6990–6995.
   PubMed Web of Science ®Google Scholar
• Engel T, Goni-Oliver P, Lucas JJ, et al. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem. 2006;99:1445–1555.
   PubMed Web of Science ®Google Scholar
• Tolosa E, Litvan I, Höglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014;29:470–478.
   PubMed Web of Science ®Google Scholar
• Wischik CM, Edwards PC, Lai RY, et al. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA. 1996;93:11213–11218.
   PubMed Web of Science ®Google Scholar
• Seripa D, Solfrizzi V, Imbimbo BP, et al. Tau-directed approaches for the treatment of Alzheimer‘s disease: focus on leuco-methylthioninium. Expert Rev Neurother. 2016;16:259–277.
   PubMed Web of Science ®Google Scholar
• Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer‘s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388:2873–2884.
   PubMed Web of Science ®Google Scholar
• TauRx Pharmaceuticals, Press Release. 10th International Conference on Frontotemporal Dementias; September 4, 2016; Munich, 2016 August 31-September 2.
   Google Scholar
• Min SW, Chen X, Tracy TE, et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med. 2015;21:1154–1162.
   PubMed Web of Science ®Google Scholar
• Lagraoui M, Sukumar G, Latoche JR, et al. Salsalate treatment following traumatic brain injury reduces inflammation and promotes a neuroprotective and neurogenic transcriptional response with concomitant functional recovery. Brain Behav Immun. 2017;61:96–109.
   PubMed Web of Science ®Google Scholar
• Rosenmann H, Grigoriadis N, Karussis D, et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol. 2006;63:1459–1467.
   PubMed Web of Science ®Google Scholar
• Panza F, Solfrizzi V, Seripa D, et al. Tau-based therapeutics for Alzheimer‘s disease: active and passive immunotherapy. Immunotherapy. 2016;8:1119–1134.
   PubMed Web of Science ®Google Scholar
• Kontsekova E, Zilka N, Kovacech B, et al. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer‘s disease model. Alzheimers Res Ther. 2014;6:44.
   PubMed Web of Science ®Google Scholar
• Kontsekova E, Zilka N, Kovacech B, et al. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer‘s disease. Alzheimers Res Ther. 2014;6:45.
   PubMed Web of Science ®Google Scholar
• Paholikova K, Salingova B, Opattova A, et al. N-terminal truncation of microtubule associated protein tau dysregulates its cellular localization. J Alzheimers Dis. 2015;43:915–926.
   PubMed Web of Science ®Google Scholar
• Novak P, Schmidt R, Kontsekova E, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer‘s disease: a randomised, double-blind, placebo-controlled,phase 1 trial. Lancet Neurol. 2017;16:123–134.
   PubMed Web of Science ®Google Scholar
• Panza F, Logroscino G. Anti-tau vaccine in Alzheimer‘s disease: a tentative step. Lancet Neurol. 2017;16:99–100.
   PubMed Web of Science ®Google Scholar
• Shoeibi A, Olfati N, Litvan I. Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy. Expert Opin Investig Drugs. 2018;27:349–361.
   PubMed Web of Science ®Google Scholar
• Bright J, Hussain S, Dang V, et al. Human secreted tau increases amyloid-beta production. Neurobiol Aging. 2015;36:693–709.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K. Alzheimer’s pathogenesis: is there neuron-to-neuron propagation?. Acta Neuropathol. 2011;121:589–595.
   PubMed Web of Science ®Google Scholar
• Dai CL, Chen X, Kazim SF, et al. Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. J Neural Transm. 2015;122:607–617. (Vienna)
   PubMed Web of Science ®Google Scholar
• Jarskog LF, Dong Z, Kangarlu A, et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology. 2013;38:1245–1252.
   PubMed Web of Science ®Google Scholar
• Javitt DC, Buchanan RW, Keefe RS, et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res. 2012;136:25–31.
   PubMed Web of Science ®Google Scholar
• Vulih-Shultzman I, Pinhasov A, Mandel S, et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther. 2007;323:438–449.
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Jouroukhin Y, Gray AJ, et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer’s disease. J Pharmacol Exp Ther. 2008;325:146–153.
   PubMed Web of Science ®Google Scholar
• Jouroukhin Y, Ostritsky R, Assaf Y, et al. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol Dis. 2013;56:79–94.
   PubMed Web of Science ®Google Scholar
• Morimoto BH, Schmechel D, Hirman J, et al. A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. Dement Geriatr Cogn Disord. 2013;35:325–336.
   PubMed Web of Science ®Google Scholar
• Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13:676–685.
   PubMed Web of Science ®Google Scholar
• Khanna MR, Kovalevich J, Lee VM, et al. Therapeutic strategies for the treatment of tauopathies: hopes and challenges. Alzheimers Dement. 2016;12:1051–1065.
   PubMed Web of Science ®Google Scholar
• Merrilees J. A model for management of behavioral symptoms in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2007;21:S64–S69.
   PubMed Web of Science ®Google Scholar
• Cheng ST, Chow PK, Song YQ, et al. Mental and physical activities delay cognitive decline in older persons with dementia. Am J Geriatr Psychiatry. 2014;22:63–67.
   PubMed Web of Science ®Google Scholar
• Kortte KB, Rogalski EJ. Behavioural interventions for enhancing life participation in behavioural variant frontotemporal dementia and primary progressive aphasia. Int Rev Psychiatry. 2013;25:237-245.
   Google Scholar
• Tippett DC, Hillis AE, Tsapkini K. Treatment of primary progressive aphasia. Curr Treat Options Neurol. 2015;17:362.
   PubMed Web of Science ®Google Scholar
• Sud R, Geller ET, Schellenberg GD. Antisense-mediated exon skipping decreases tau protein expression: a potential therapy for tauopathies. Mol Ther Nucleic Acids. 2014;3:e180.
   PubMedGoogle Scholar
• Kalbfuss B, Mabon SA, Misteli T. Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J Biol Chem. 2001;276:42986–42993.
   PubMed Web of Science ®Google Scholar
• DeVos SL, Miller RL, Schoch KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9:eaag0481.
   PubMed Web of Science ®Google Scholar
• Soga S, Akinaga S, Shiotsu Y. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des. 2013;19:366–376.
   PubMed Web of Science ®Google Scholar
• Dickey CA, Dunmore J, Lu B, et al. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. Faseb J. 2006;20:753–755.
   PubMed Web of Science ®Google Scholar
• Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med. 2004;10:283–290.
   PubMed Web of Science ®Google Scholar
• Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 2001;292:1552–1555.
   PubMed Web of Science ®Google Scholar
• Ozcelik S, Fraser G, Castets P, et al. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS One. 2013;8:e62459.
   PubMed Web of Science ®Google Scholar
• Siman R, Cocca R, Dong Y. The mTOR inhibitor rapamycin mitigates perforant pathway neurodegeneration and synapse loss in a mouse model of early-stage alzheimer-type tauopathy. PLoS One. 2015;10:e0142340.
   PubMed Web of Science ®Google Scholar
• Orr ME, Sullivan AC, Frost B. A brief overview of tauopathy: causes, consequences, and therapeutic strategies. Trends Pharmacol Sci. 2017;38:637–648.
   PubMed Web of Science ®Google Scholar
• Liu F, Iqbal K, Grundke-Iqbal I, et al. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer‘s disease. Proc Natl Acad Sci U S A. 2004;101:10804–10809.
   PubMed Web of Science ®Google Scholar
• Liu F, Shi J, Tanimukai H, et al. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer‘s disease. Brain. 2009;132:1820–1832.
   PubMed Web of Science ®Google Scholar
• Borghgraef P, Menuet C, Theunis C, et al. Increasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of Tau.P301L mice. PLoS One. 2013;8:e84442.
   PubMed Web of Science ®Google Scholar
• Hastings NB, Wang X, Song L, et al. Inhibition of O-GlcNAcase leads to elevation of OGlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice. Mol Neurodegener. 2017;12:39.
   PubMed Web of Science ®Google Scholar
• Mattsson N, Scho¨ Ll M, Strandberg O, et al. 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer’s disease. EMBO Mol Med. 2017;9:1212–1223.
   PubMed Web of Science ®Google Scholar
• Franzmeier N, Rubinski A, Neitzel J, et al. Alzheimer’s disease neuroimaging initiative. functional connectivity associated with tau levels in ageing, Alzheimer‘s, and small vessel disease. Brain. 2019;awz026. Epub ahead of print. doi:10.1093/brain/awz026
   Web of Science ®Google Scholar
• Golbe LI, Ohman‐Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain. 2007;130:1552–1565.
   PubMed Web of Science ®Google Scholar
• Mioshi E, Hsieh S, Savage S, et al. Clinical staging and disease progression in frontotemporal dementia. Neurology. 2010;74:1591–1597.
   PubMed Web of Science ®Google Scholar
• Semler E, Anderl-Straub S, Uttner I, et al. A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. Alzheimers Res Ther. 2018;10:41.
   PubMed Web of Science ®Google Scholar